140 related articles for article (PubMed ID: 37060187)
1. Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants.
Ucpinar S; Smith PF; Long L; Li F; Yan H; Wadhwa J; Chu KA; Shu J; Nunn P; Li M
Clin Transl Sci; 2023 Jul; 16(7):1210-1219. PubMed ID: 37060187
[TBL] [Abstract][Full Text] [Related]
2. The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.
Takahashi RH; Malhi V; Liederer BM; Cho S; Deng Y; Dean B; Nugteren J; Yost E; Al-Sayah MA; Sane R; Kshirsagar S; Ma S; Musib L
Drug Metab Dispos; 2023 Oct; 51(10):1332-1341. PubMed ID: 37524543
[TBL] [Abstract][Full Text] [Related]
3. A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects.
Ucpinar S; Darpo B; Neale A; Nunn P; Shu J; Chu KA; Kavanagh M; Xue H; Phiasivongsa P; Thomas D; Smith PF
Clin Transl Sci; 2022 Jun; 15(6):1507-1518. PubMed ID: 35301810
[TBL] [Abstract][Full Text] [Related]
4. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Johne A; Scheible H; Becker A; van Lier JJ; Wolna P; Meyring M
Invest New Drugs; 2020 Oct; 38(5):1507-1519. PubMed ID: 32221754
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Excretion, and Mass Balance of [
Ambery C; Young G; Fuller T; Lazaar AL; Pereira A; Hughes A; Ramsay D; van den Berg F; Daley-Yates P
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):901-910. PubMed ID: 30230263
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers.
Miah K; Vishwanathan K; Scarfe G; Li Y; Hara I; Cantarini M; Argue J; Menakuru SR
Clin Pharmacol Drug Dev; 2023 Apr; 12(4):424-435. PubMed ID: 36808891
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a
Singh RSP; Dowty ME; Salganik M; Brodfuehrer JI; Walker GS; Sharma R; Beebe JS; Danto SI
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):815-825. PubMed ID: 35506501
[TBL] [Abstract][Full Text] [Related]
8. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ; Efraim M; Mayer J; Trněný M; McDonald V; Bird R; Regenbogen T; Garg M; Kaplan Z; Tzvetkov N; Choi PY; Jansen AJG; Kostal M; Baker R; Gumulec J; Lee EJ; Cunningham I; Goncalves I; Warner M; Boccia R; Gernsheimer T; Ghanima W; Bandman O; Burns R; Neale A; Thomas D; Arora P; Zheng B; Cooper N
N Engl J Med; 2022 Apr; 386(15):1421-1431. PubMed ID: 35417637
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
10. The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [
Burkard U; Desch M; Shatillo Y; Wunderlich G; Mack SR; Schlecker C; Teitelbaum AM; Liu P; Chan TS
Clin Drug Investig; 2022 Jan; 42(1):87-99. PubMed ID: 34936055
[TBL] [Abstract][Full Text] [Related]
11. Absolute Bioavailability of Osimertinib in Healthy Adults.
Vishwanathan K; So K; Thomas K; Bramley A; English S; Collier J
Clin Pharmacol Drug Dev; 2019 Feb; 8(2):198-207. PubMed ID: 29683562
[TBL] [Abstract][Full Text] [Related]
12. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
13. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
14. A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a
Qiu R; Sharma R; Wei H; Kirkovsky L; Zhou Y; Martin DDA; Banfield C; Dowty ME
Br J Clin Pharmacol; 2023 Oct; 89(10):3056-3066. PubMed ID: 37183779
[TBL] [Abstract][Full Text] [Related]
15. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24-hydroxylase inhibitor soticlestat in healthy volunteers.
Yin W; Ballard TE; Zhu SX; Hsiao S; Chen H; Li Y; Chowdhury SK; Stevenson A; Hui T; Hunt A; Asgharnejad M; Han S
Br J Clin Pharmacol; 2024 Feb; 90(2):516-527. PubMed ID: 37771051
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Morcos PN; Yu L; Bogman K; Sato M; Katsuki H; Kawashima K; Moore DJ; Whayman M; Nieforth K; Heinig K; Guerini E; Muri D; Martin-Facklam M; Phipps A
Xenobiotica; 2017 Mar; 47(3):217-229. PubMed ID: 27180975
[TBL] [Abstract][Full Text] [Related]
18. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Scheible H; Dyroff M; Seithel-Keuth A; Harrison-Moench E; Mammasse N; Port A; Bachmann A; Dong J; van Lier JJ; Tracewell W; Mitchell D
Clin Transl Sci; 2021 Nov; 14(6):2420-2430. PubMed ID: 34374206
[TBL] [Abstract][Full Text] [Related]
19. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
[TBL] [Abstract][Full Text] [Related]
20. A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [
Helmer E; Nicolas JM; Long J; Roffel AF; Jones E; Chanteux H; Diaz N; Garratt H; Bosje T
J Clin Pharmacol; 2017 Dec; 57(12):1582-1590. PubMed ID: 28650526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
